Stock LYEL LYELL IMMUNOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-09 pm EDT 		5-day change 1st Jan Change
2.68 USD +7.20% Intraday chart for Lyell Immunopharma, Inc. +11.67% +38.14%
May. 06 Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
May. 06 Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company appears to be poorly valued given its net asset value.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
LYELL IMMUNOPHARMA, INC. Stock Lyell Immunopharma, Inc.
+38.14% 637M
C
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.97% 108B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.21% 105B
B+
ARGENX SE Stock argenx SE
+1.57% 23.46B
B
BIONTECH SE Stock BioNTech SE
-12.77% 21.72B
B+
GENMAB A/S Stock Genmab A/S
-7.05% 18.64B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.64% 17.45B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.50% 17.19B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.00% 13.99B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.20% 12.53B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LYEL Stock
  4. Ratings Lyell Immunopharma, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW